LYT-100
Study at a Glance
Estimated Time Commitment
To be discussedEligibility
Post Acute COVID patients who continue to have shortness of breath after hospital discharge; Any form of oxygen use qualifies; must enroll within 90 days of original COVID diagnosis unless intubated, and then is extended another 6 weeks.Diagnosis Required
Post Acute COVID diagnosisDiseases Being Studied
SARS-CoV-2Sponsor: PureTech
Coordinating Center/CRO: Clinipace
Primary Objective: To evaluate the effect of LYT-100 on the change in distance walked on the six-minute walk test performed in line with the American Thoracic Society/European Respiratory Society Guidelines.
Study drug: LYT-100 (Deupirfenidone) vs placebo capsules twice day for 91 days; added open label extension for additional 90 days
Study Progress: Enrollment goal reached globally, but sponsor wants an additional 10 US subjects so that a sufficient number ofsubjects with quality of lifedata can be captured
Current enrollment: 3
Meet Your Clinical Research Team
Contact us
Principal Investigator: All Infectious Diseases FacultyFor questions on this study, please email Dr. Barbara Taylor